In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in oncology biosimilars.
Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.
MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
Description
